Table 3

Clinicopathological characteristics of 21 NSCLC cases treated with gefitinib

A
No.GenderAge (y)Smoking statusHistologyECOG performance statusNo. of prior chemotherapyRadiotherapyPeriod from surgery to gefitinib therapy (mo)EGFR mutation (exon)Response to gefitinib
1F60NeverAdenocarcinoma22+19.619CR
2M64NeverAdenocarcinoma12+5.419PR
3M65SmokerAdenocarcinoma2228.419PR
4M57SmokerAdenocarcinoma124319PR
5M40NeverAdenocarcinoma12+21.119PR
6F59NeverAdenocarcinoma11+21.521PR
7F60NeverAdenocarcinoma03+16.721PR
8F68NeverAdenocarcinoma2135.221PR
9M70SmokerAdenocarcinoma2163.9PR
10M77SmokerSquamous cell carcinoma22+18.8PR
11F77NeverAdenosquamous cell carcinoma11+1021NC
12F75NeverAdenocarcinoma03+51.4NC
13F73SmokerSquamous cell carcinoma2117.6NC
14M77SmokerSquamous cell carcinoma12+11.8PD
15M70SmokerLarge cell carcinoma13+14.3PD
16M68SmokerAdenocarcinoma0137.8NC
17M63SmokerAdenocarcinoma1317NC
18M58SmokerAdenocarcinoma32+17.9NC
19F55SmokerSquamous cell carcinoma13+105PD
20M49SmokerAdenocarcinoma12+14.3NC
21M62SmokerAdenocarcinoma1287.1NC
B
Responder (n = 10)Nonresponder (n = 11)
EGFR mutation81
Median age (range), y62 (40-77)68 (49-77)
Gender
    Male67
    Female44
Smoking history
    Never62
    Smoker49
Histology
    Adenocarcinoma96
    Squamous cell carcinoma13
    Adenosquamous cell carcinoma01
    Large cell carcinoma01
ECOG performance status
    0-159
    251
    301
  • NOTE: The case that achieved complete response or partial response based on ECOG criteria was considered as responder and no change or progressive disease was considered as no-responder.

    Abbreviations: CR, complete response; PR, partial response; NC, no change; PD, progressive disease; ECOG, Eastern Cooperative Oncology Group.